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Background: Cognitive Behaviour Therapy for Insomnia (CBT-I) delivered through the Internet is effective as a
treatment in reducing insomnia in individuals seeking help for insomnia. CBT-I also lowers levels of depression in
this group. However, it is not known if targeting insomnia using CBT-I will lower depressive symptoms, and thus
reduce the risk of major depressive episode onset, in those specifically at risk for depression. Therefore, this study
aims to examine whether Internet delivery of fully automated self-help CBT-I designed to reduce insomnia will
prevent depression.
Method/design: A sample of 1,600 community-dwelling adults (aged 18–64), who screen positive for both subclinical
levels of depressive symptoms and insomnia, will be recruited via various media and randomised to either a 9-week
online insomnia treatment programme, Sleep Healthy Using The internet (SHUTi), or an online attention-matched
control group (HealthWatch). The primary outcome variable will be depression symptom levels at the 6-month
post-intervention on the Patient Heath Questionnaire-9 (PHQ-9). A secondary outcome will be onset of major
depressive episodes assessed at the 6-month post-intervention using ‘current’ and ‘time from intervention’ criteria from
the Mini International Neuropsychiatric Interview.
Discussion: This trial is the first randomised controlled trial of an Internet-based insomnia intervention as an indicated
preventative programme for depression. If effective, online provision of a depression prevention programme will
facilitate dissemination.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR), Registration number: ACTRN12611000121965.Background
Depression is a leading cause of disability throughout
the world. In the US, depression is estimated to repre-
sent a total lifetime economic cost for all those affected
of 2.1 trillion dollars and at an individual level a lifetime
loss of $300,000 per family affected [1]. Globally,
depression is the leading cause of disease burden as
measured by years lost to disability (YLD), representing
roughly 20 million years and 31 million years lost
because of disability annually for males and females
respectively [2].* Correspondence: john.gosling@anu.edu.au
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reproduction in any medium, provided the orThere is now considerable evidence that major
depressive disorder (MDD) can be prevented [3]. How-
ever, the best methods to prevent depression are still
debated [4]. Although cognitive behaviour therapy as
an intervention is strongly supported [5], it is not clear
whether interventions to prevent depression should
take an indicated, selective or universal approach [3].
The present trial (The GoodNight Study) aims to
prevent depression by reducing insomnia in individuals
with depression symptoms, although not meeting
criteria for MDD, and thus represents an indicated
prevention trial of depression using an intervention
designed to improve sleep.
In this study protocol paper, the development of the
GoodNight Study is described. We provide a descriptionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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a rationale for our approach, then outline the methods,
research design and analysis strategy, followed by a brief
discussion of the potential implications of the study.
The relationship between insomnia and depression
The relationship between insomnia and depression has
received considerable attention in the past decade. Focus
has shifted from the view that insomnia is a symptom, or
sequala, of depression to one in which it is conceptualised
as a related but not totally dependent phenomenon [6].
Supporting this, insomnia is commonly unresponsive to
otherwise successful treatment for depression, being the
most common residual symptom following completion
of either pharmacological or psychological depression
treatment [7,8], and the timing of insomnia onset more
often than not precedes the onset of a depressive episode
[9]. Insomnia is a strong independent risk factor for both
initial episodes of MDD and episodic recurrence [10]. All
major longitudinal North American psychiatric epidemio-
logical studies confirm this finding: the Epidemiological
Catchment Area study [11], the National Comorbidity
Study [12], Johns Hopkins Precursor study [13], the
Stirling County Study 9 [14] and those from Europe
[15] and elsewhere [16]. Work from the Zurich Cohort
[17] and other multiply sampled studies [18] has shown
that this effect is independent of previous episodes of
MDD and subclinical symptoms of depression. Recent
evidence even suggests that insomnia treatment can
positively affect the treatment course and outcome for
non-sleep aspects for a range of psychiatric disorders
[19]. Self-help therapy for insomnia is also associated
with improvements in depression and anxiety [20-24].
While not demonstrating a causal association, this set
of findings suggests that the treatment of insomnia may
lower depressive symptoms and prevent the develop-
ment of a first or recurrent episode of major depressive
disorder [25].
Cognitive Behavioural Therapy for Insomnia (CBT-I)
is amongst the most effective treatments for insomnia
[26]; it is as effective as pharmacotherapy in the long
term, with the added benefit of improvements persisting
beyond cessation of treatment [27] and without the
possible side effects. Recent evidence also suggests that
CBT-I can have the benefit of reducing comorbid depres-
sion, decreasing both depression-related sleep-disturbance
[28,29] and depressive symptomatology [19,29]. There
is preliminary evidence suggesting that Internet-based
CBT-I in individuals reporting with insomnia also
results in reduced levels of depressive symptoms, in
addition to significantly reducing insomnia [30]. How-
ever, the question of whether major depressive episodes
can be prevented by treating insomnia has not yet been
answered.The current trial uses a cognitive behaviour therapy
(CBT) intervention for sleep, delivered as a web-based
programme, SHUTi [31]. The choice of an online applica-
tion such as SHUTi was motivated by the observation that
Internet programmes can offer the intervention to a large
number of individuals [32]. Online interventions, if effect-
ive, have wide-scale reach and can be disseminated for little
cost [33], making them ideal for prevention at a population
level. They are also often preferred over traditional face-
to-face methods for their ability to provide anonymity,
convenience, and ability to be used at home [34].
Sixteen hundred community-dwelling adults from
Australia will be randomised to one of two conditions:
SHUTi, an online Cognitive Behavioural Therapy in-
tervention for Insomnia, shown to be effective in decreas-
ing insomnia severity and improving sleep efficiency
in two US trials [31,35], or HealthWatch, an attention-
matched control condition used in previous RCTs run
through the Centre for Mental Health Research, ANU
[36,37].
Methods/design
Sample and recruitment
A total of 1,600 community-dwelling adults from across
Australia with insomnia and subclinical levels of depres-
sion will be recruited using advertisements placed on
popular online social networking sites [38,39], through
sleep and/or mental health associations and foundations,
through Google Advertising [38], and through media
releases and newspaper articles. We expect that those at
risk of insomnia or experiencing insomnia will select to
click on the advertisement, where they will find informa-
tion about the trial. Participants will then proceed to a
screening page to determine eligibility for the study.
Screening
At screening, respondents indicate whether they are aged
between 18 and 64, have a valid email address and tele-
phone number, and live in Australia. If those interested
are eligible (see below for criteria), they will complete the
Bergen Insomnia Scale (BIS) [40] and the Patient Health
Questionnaire 9 (PHQ-9) [41]. If insomnia and subclinical
depression are indicated (see below), respondents will
be provided with a study information sheet and invited
to give informed consent for a telephone call from trial
staff to check eligibility and subsequently to take part
in the study if ultimately found eligible. This telephone-
based diagnostic interview will then be conducted by an
experienced telephone interviewer. Sections of the Mini
International Neuropsychiatric Interview (MINI) [42]
relating to ‘current’ and ‘lifetime’ depression, current mania,
panic disorder, social phobia, and generalised anxiety as
well as a modified version of the Morin Insomnia Inter-
view used in the original trial of SHUTi [43] will be
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ten daily sleep diary entries within a 2-week period prior
to randomisation.
Inclusion/exclusion criteria
Initial eligibility criteria are age 18 to 64; Bergen Insomnia
Scale score of 3 or above on at least one of the first four
items and a score of 3 or above on at least one of the last
two items; and a score greater than 4 but less than 20
on the PHQ-9. Participants will also be excluded if their
bedtime is outside of the hours of 8:00 p.m. to 2:00 a.m.
more than twice a week, notwithstanding if this is due to
insomnia. Similarly, participants will be excluded if their
rising time is outside of the hours of 4:00 a.m. to 10:00 a.m.
more than twice a week, again notwithstanding if this is
due to insomnia. These stipulations will eliminate respon-
dents who are shift workers, carers of young children, or
who have other commitments that are likely to interfere
with their ability to adhere to a regular nighttime sleep pat-
tern. Participants will also be excluded if they are pregnant;
do not have reliable Internet access at home or at work;
cannot comfortably read English; have ever been diagnosed
with psychosis, schizophrenia, or bipolar mood disorder
by a psychiatrist; or are currently undergoing a non-drug
treatment programme for insomnia with a health profes-
sional. Potential participants will also need to consent to a
telephone-based diagnostic interview and supply at least
one telephone number and one active email address.
In the diagnostic telephone interview, participants must
meet criteria for insomnia on Morin’s modified diagnostic
insomnia interview. These criteria include: (a) sleep-onset
insomnia and/or sleep maintenance insomnia (>30 min
for at least 3 nights/week), (b) insomnia symptoms lasting
at least 1 month, and (c) sleep disturbance (or associated
daytime fatigue) causing significant distress or impairment
in social, occupational, or other areas of functioning.
Participants will be excluded on the basis of this inter-
view if they have any other sleep disorder, have had any
medication changes in the preceding 3 months, have a
medical illness accounting for their sleep disturbance,
or are currently receiving formal psychological treatment
for insomnia. On the MINI [42], participants must fail to
meet 2-week diagnostic criteria for MDD and lifetime
criteria for bipolar mood disorder. Participants with
suicidal plans or attempts in the previous 2 weeks will
also be excluded. These participants will be contacted
by a clinical psychologist and provided with appropriate
referral information.
Experimental design and conditions
Experimental condition—online cognitive behavioural
therapy for insomnia: SHUTi
The intervention condition utilises SHUTi, an online in-
somnia intervention [43] based on Cognitive BehaviourTherapy for Insomnia (CBT-I). SHUTi incorporates six
modules or Cores: introduction/overview, sleep restriction
and stimulus control 1sleep restriction and stimulus con-
trol 2, cognitive restructuring, sleep hygiene, and relapse
prevention.
Once individuals have been deemed eligible and provided
access to SHUTi, they are presented with a personalised
homepage when first logged in. This homepage provides
information to the user regarding their progress, tasks to
complete (including alerts about sleep diary completion
and Core assignments), a tailored Sleep Window, and op-
tions for navigating the programme. There is an Informa-
tion Centre on the left of the screen, allowing access to
the main sections of the site: Home, Diaries, Cores, and
My Stuff (where users can access both static and dynamic-
ally generated printable documents from each Core as well
as link to stories and expert videos in the intervention).
Alerts as to the progress and upcoming assignments are
also displayed. Sleep diaries and a diary calendar can also
be accessed through the Information Centre tabs. Tabs
entitled “How to use”, “Contact Us”, and “Disclaimer”
are accessible at any time. “How to use” provides a brief
tutorial to the user on how best to use the programme.
“Contact Us” and “Disclaimer” provide contact details and
a reminder that the contents of SHUTi are educational
only and are not intended to replace the advice of a phys-
ician. See Figure 1 for a detailed schematic of the SHUTi
framework.
Participants are encouraged to complete sleep diaries
[44] on a daily basis throughout their use of SHUTi.
SHUTi relies on sleep diary data that are entered by the
user to track progress and to tailor programme recom-
mendations. The sleep diary consists of 11 questions about
the user’s sleep, including the hour of bedtime, minutes to
fall asleep, number of night time awakenings, duration of
night time awakenings, hour of awakening in the morning,
hour of rising (getting out of bed) in the morning, length
of daytime naps, amount of alcohol consumed, and a
description of any sleep aids that were used. Users are
also asked to rate the quality of their sleep on a 5-point
scale from very poor to very good. Information recorded
through daily sleep diaries is then used by the SHUTi
system to calculate a user’s sleep efficiency and to assign,
on a weekly basis, personalised sleep windows, i.e. the
period of time in which the participant is instructed to
sleep. Users are told that they should not sleep outside of
this sleep window. In the 7 days between each Core, users
must enter five of seven diaries to be assigned a new sleep
window. This essential component of the programme
restricts the hours during which a user is instructed to
sleep/stay in bed in an effort to increase sleep efficiency.
Algorithms have been developed to determine whether
the sleep window should be increased, decreased, or main-
tained. Users select their rising time and the programme
Figure 1 SHUTi framework. Shows a schematic of the Sleep Healthy Using the Internet (SHUTi) framework.
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also able to view a flexible graphical representation of their
sleep data from within the Diary section of the system.
The SHUTi system operates on a graduated framework,
with users gaining access to a new Core 1 week after the
previous Core has been completed. In addition to feed-
back about sleep pattern and tailored sleep windows, each
Core acts as an online analogue for the weekly sessions
typically used when delivering CBT in a face-to-face for-
mat. Each Core follows the same general structure: review
of the previous weeks’ homework with feedback, review of
diary data and revision to the Sleep Window, a summary
of what will be learned in the current Core and why
this information is important, new primary content, a
homework screen that lists suggestions for how to
improve sleep over the coming week, and a summary
screen that provides a review of the main points pre-
sented in the Core. Both the homework and summary
screens can be printed directly from the Core, as well
as from the My Stuff section of the programme, which
contains all static and dynamic documents, as well as
all stories and videos, from each Core maintained in a
convenient location. The main content screens for each
Core address a unique aspect of insomnia treatment
through a variety of interactive features, including a
variety of ‘pop up’ buttons (e.g., myth/reality buttons
or “learn more” buttons that provide in-depth information
about a topic), animations that provide a topic visual to
enhance comprehension, quizzes to test a user’s know-
ledge and impart additional information, and a series of
vignettes or stories presented in both high-quality video
and pictorially.In addition to the tailoring in each Core, the programme
also employs personalised goal-setting exercises. For
example, at the beginning of the programme, users are
asked to set specific targets for different aspects of their
sleep including sleep onset latency, number of nighttime
awakenings, and time spent awake in the middle of the
night. At the end of the study, they are asked to re-
evaluate their goals and to track their progress towards
meeting them. Further tailoring occurs throughout the
SHUTi programme in the form of various symptom
checklists and homework assignments. Additional de-
tails of SHUTi can be found in Thorndike et al. [43].
Attention-matched control
The attention-matched control condition uses a 9-week
version of HealthWatch, an Internet-delivered interactive
lifestyle website with no specific mental health or sleep-
related content. In previous trials HealthWatch [36,37,45]
was not associated with reductions in depression symp-
toms [37]. Modules within HealthWatch are comprised of
information pertaining to environmental health, nutrition
myths, heart health, activity, medication, the effects of
temperature, oral health, blood pressure and cholesterol,
calcium, and back pain, as well as surveys about each of
these topics each week.
Assessments
Assessments are completed at pretest; immediate post-test;
and 6-, 12-, and 18-month follow-up. Pretest assessment
includes demographic information; outcome measures
pertaining to insomnia (Insomnia Severity Index-ISI [46]),
depression symptomatology (PHQ-9 [41]), anxiety (Gener-
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tion (from the Psychiatric Symptom Frequency scale-PSF
[48]), disability (World Health Organisation Disability
Assessment Schedule, 12 items-WHODAS-12 [49]), phys-
ical health and physical activity (International Physical Ac-
tivity Questionnaire, Short Form-IPAQ SF [50]), attitudes
toward help-seeking (Actual Help Seeking Questionnaire-
AHSQ [51]/General Help Seeking Questionnaire-GHSQ
[52]), and potential correlates of treatment outcome such
as dysfunctional beliefs about sleep (Dysfunctional Beliefs
About Sleep measure-DBAS [53]), sleep-threat monitoring
(Sleep-Associated Monitoring Index-SAMI [54]), condi-
tion preference, and perceived need for treatment. Partici-
pants’ cognitive functioning will also be measured during
the telephone-based diagnostic interview (Brief Test of
Adult Cognition via Telephone-BTACT, Speed of Process-
ing Subscale [55]). During the intervention phase of the
study, participants will complete ongoing assessments on
the ISI [46,56] and, to measure ongoing depression and
anxiety symptomatology, the PHQ-9 [41] and GAD-7 [47]
respectively at weeks 2, 4, 6, and 8.
At post-test, participants will complete an online ques-
tionnaire similar to that at pretest (see Table 1) in addition
to receiving a telephone call in which they will again be
administered the MINI [42] and the BTACT [57].
At 6-, 12-, and 18-month follow-up, participants will
again complete online assessments and at 6- and 18-
month follow-up will receive a telephone call in which
they will be administered the MINI and the BTACT.
Study hypotheses
Primary outcome
Participants receiving the SHUTi intervention will have
lower levels of depression symptomatology on the PHQ-
9, controlling for pretest depression levels, at 6 months
compared to participants in the attention-matched con-
trol condition.
Secondary outcomes
The incidence of depressive episodes in the period since
pre-test at 6-month follow-up will be lower in the
SHUTi intervention arm compared to the control con-
dition. This will be measured using the MINI. Related
outcomes include a lower incidence of depressive epi-
sodes at 18-month follow-up. SHUTi participants will
also have lower PHQ-9 scores at post-test, 12- and 18-
month follow-up relative to controls, along with lower
levels of insomnia on the Insomnia Severity Index, lower
anxiety levels as measured by the GAD-7 [47] scores,
lower suicidal ideation as measured using the PSF suicide
items [48], and lower sleep and depression-related
disability (i.e., impact on day-to-day functioning) as
measured by the WHODAS-12 [58]. Compared to the
control group, SHUTi intervention participants will alsodemonstrate increases in cognitive functioning, as mea-
sured by the BTACT [58], and increases in help seeking,
as measured using the GHSQ [51] and AHSQ [52].
Cost effectiveness
The incremental effectiveness will be determined by the
difference in change scores in the intervention and control
groups on the depression measure PHQ-9 [41]. The gen-
eric effectiveness will be measured using HRQOL from
the SF-12 (Short Form 12) [59] and the WHODAS-12
(World Health Organization Disability Assessment Sched-
ule, 12-item version) [58].
Costs will be measured from a health service and
productivity perspective. Health service usage will be
ascertained through:
i). self-report measurement (using the Client Service
Receipt Inventory, CSRI) [60] and service use
calculated on the basis of standard service costs, and
ii). data from the Australian Medicare Benefits Scheme/
Pharmaceutical Benefits Scheme will be matched up
with known costs of such services,
iii).extra out-of-pocket expenses associated with
accessing these services, and
iv).costs associated with production loss relating to days
out of role due to disability.
Power
While the primary outcome variable of the study is a
participant’s score on the PHQ-9 (a continuous measure),
power calculations were based on rates of caseness for
MDD as a larger sample is required to be able to detect
changes in this secondary, but important, binary outcome.
Estimates of power to detect differences in the proportion
of probable cases of MDD as indicated by the PHQ-9 at
6-month follow-up were based on the estimated rate of
onset of MDD in our target group and the anticipated
effect of the SHUTi intervention. Based upon data from a
subsample of participants in the PATH Through Life study
[61] with comparable initial depression scores, and adjust-
ing for the length of observation (6 months for this study
vs. 4 years for PATH), approximately 15% of the no-
intervention group with subclinical levels of depressive
symptoms is expected to progress to probable MDD (a
score of 15 or above on the PHQ-9, classified as mod-
erately severe to severe depression and indicative of
probably MDD [62]) within 6 months. We expect, based
on data from previous research utilising SHUTi, a reduc-
tion of 40% of incident episodes in the treated group. For
a total sample of 80% power, with a 40% reduction in risk
in a sample with a pre-test incidence rate of 15%, a total
sample size of 972 is needed. Economies of scale inherent
in our automatised trial implementation should allow us
to recruit a total sample of 1,600. This will maintain power
Table 1 Assessment measures in the GoodNight study
Online
screener
Screening telephone
interview
Pre-test
survey
During
intervention
Immediate
post-test
6-, 18-month f/u 12-month f/u
PHQ-91 X X X X X X
BIS2 X
Secondary eligibility criteria X
MINI3 X X X
Adapted Morin insomnia interview X
BTACT4 X X X
Demographics X
Condition preference X
Perceived need for treatment X
GAD-75 X X X X X
PSF6 (suicidal ideation items) X X X X
DBAS-167 X X X X
SAMI8 (shortened) X X X X
IPAQ SF9 X X X X
AHSQ/GHSQ10 X X X X
CSRI11 X X X X
SF1212 X X X X
WHODAS 1213 X X X X
ISI14 X X X X X
Sleep diaries X X (SHUTi) X X X
Adherence questionnaire X
Internet evaluation and utility X
1Patient Health Questionnaire-9 item.
2Bergen Insomnia Scale.
3Mini-International Neuropsychiatric Interview.
4Brief Test of Adult Cognition by Telephone.
5General Anxiety Disorder-7 item.
6Psychiatric Symptom Frequency scale.
7Dysfunctional Beliefs About Sleep-16 item.
8Sleep-Associated Monitoring Index.
9International Physical Activity Questionnaire-Short Form.
10Actual Help Seeking Questionnaire/General Help Seeking Questionnaire.
11Client Service Receipt Inventory.
12Short Form-12 item.
13World Health Organisation Disability Assessment Schedule-12 item.
14Insomnia Severity Index.
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needed = 1,526) or if recruitment rates are less than antici-
pated. The target sample size will also maintain a power of
80% if the efficacy of the intervention is as low as 30%.
Random allocation procedure
Randomisation will occur immediately following comple-
tion of the pre-assessment sleep diary phase using auto-
mated procedures integrated into the trial management
software. Participants will be stratified by age and gender.
Statistical analysis
Primary analyses will be undertaken on an intent-to-treat
(ITT) basis, including data for all participants who wererandomised, irrespective of their level of adherence to the
intervention or whether they withdrew at any point in
time. Participants with missing data will be accommo-
dated using linear and generalised mixed-model repeated
measure (MMRM) models. Transformations, including
dichotomisation or other categorisation, will be under-
taken as necessary to meet distributional assumptions and
to accommodate outlying observations.
Ethics approval
The GoodNight Study has received ethics approval from
the Australian National University Human Research Ethics
Committee, protocol no. 2011/041.
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The prevention of depression is crucial if burden of dis-
ease attributable to this condition is to be reduced sub-
stantially. There are a number of novel features to the
present trial. It will be the first trial targeting insomnia
as a means of preventing the development of MDD. The
trial is also novel in that it attempts to attract those at
risk of depression to seek intervention by focussing on a
condition that may not be stigmatising. Finally, it uses
an online intervention that is capable of being dissemi-
nated at low cost to the community should it be found
that SHUTi is effective. With follow-up time points at 6,
12, and 18 months post-intervention, the long-term im-
pact of this intervention on depression, as well as its
impact on secondary outcomes such as anxiety, suicidal
ideation, disability, cognition, and help-seeking, can be
assessed. A thorough analysis of potential correlates of
intervention outcome will also allow for subsequent
refinement and tailoring of the programme. Use of cost-
effectiveness analyses will further provide information
about the feasibility and economic benefit of imple-
menting such an indicated prevention programme on a
population level.
Trial status
Recruitment to the GoodNight Study commenced in April
2013. The final participants are expected to complete their
18-month follow-up assessments in late 2015.
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